Introduction
Glioblastoma multiformes (GBMs) are the most common and malignant tumors in the central nervous system (Jemal et al., 2010) . The inherent single-cell invasive nature of GBMs contributes to resistance to therapy and high frequency of tumor recurrence of these tumors after maximal surgical resection, combined with radiotherapy and concurrent or adjuvant chemotherapies. The median survival time of patients with GBMs remains 14-16 months after diagnosis (Furnari et al., 2007; Wen and Kesari, 2008) . Thus, understanding the mechanisms underlying the intrinsic tumor infiltration is urgent to improve efficacy of treatments for highly invasive GBMs (Giese et al., 2003) . Recently, coordinated genomic analyses of a large cohort of clinical GBM specimens showed that the gene encoding plateletderived growth factor receptor-a (PDGFRa) was amplified in B13% of the total GBMs analyzed, ranking PDGFRa at third among the top 11 amplified genes in GBMs (TCGA, 2008) . In clinic, overexpression of PDGFRa is associated with a poor prognosis and shorter survival time for patients (Haberler et al., 2006; Furnari et al., 2007; Wen and Kesari, 2008) . Although activation of PDGFRa-specific pathway involves tumor progression of malignant GBMs, the molecular mechanisms by which PDGFRa promotes GBM growth and invasion remain largely unknown (Calzolari and Malatesta, 2010) .
The superfamily of dynamin (Dyn) includes classical Dyns and Dyn-related proteins that play important roles in endocytosis (van der Bliek et al., 1993; Damke et al., 1994) , cell migration and invasion (Kruchten and McNiven, 2006) and cancer cell proliferation (Joshi et al., 2010) . There are three different Dyn isoforms in mammalians: Dyn1 is restricted to express in neuronal cells; Dyn2 is ubiquitously expressed; and Dyn3 may be limited to brain, lung and testis (Kruchten and McNiven, 2006) . Abundant evidence implicates Dyns as movers during cell migration and invasion (McNiven et al., 2000a; Kruchten and McNiven, 2006) . For example, Dyn2 interacts with components of cytoskeleton, thereby influencing the movement of intracellular vesicles (Lee and De Camilli, 2002; Orth and McNiven, 2003) , modulating cell shape (McNiven et al., 2000b) , and affecting podosomal adhesions (Ochoa et al., 2000; Lee and De Camilli, 2002) , invadopodia (Baldassarre et al., 2003) and phagocytosis (Gold et al., 1999) . Upon PDGF stimulation, Dyn becomes markedly associated with membrane ruffles and lamellipodia, leading to increased cell migration (Cao et al., 1998; McNiven et al., 2000b; Krueger et al., 2003) . Moreover, a dominant-negative (DN) Dyn2 K44A mutant blocks PDGF-induced macropinocytosis (Schlunck et al., 2004) . However, although this evidence suggests that Dyn is involved in PDGF-stimulated cell migration and other studies show that Dyn interacts with phosphatidylinositol 3-kinase (PI3K) and phospholipase Cg-1 that are common downstream modulators for receptor tyrosine kinases (RTKs) including PDGFRa (Scaife et al., 1994) , how Dyn mediates PDGFRa-promoted cell migration is still elusive.
SHP-2 is a nonreceptor protein tyrosine phosphatase (PTP) that has been implicated in the activation of the Ras/mitogen activated protein kinase signaling by receptors for various growth factors and cytokines, including PDGFRa signaling (Neel et al., 2003; Matozaki et al., 2009) . Moreover, activating SHP-2 mutations were observed in hematological malignancies and other types of cancers including two E69K and I292M mutations in GBMs and a T22A mutation in oligodendrogliomas (Navis et al., 2010) . Most recently, PTPN11 (encoding SHP-2 protein) was identified as a 'Linker' gene for connections to various altered genes in GBMs by genomic analysis (Cerami et al., 2010) . Our recent report functionally validated this hypothesis, demonstrating that SHP-2 mediates PDGFRa-promoted tumorigenesis and tumor invasion in mouse Ink4a/Arf-null astrocytes and human glioma cells (Liu et al., 2011) . In this study, we investigated mechanisms of PDGFRa-SHP-2 stimulation of glioma cell growth and invasion. We show that Dyn2 is a downstream effector of the PDGFRa-PI3K/ SHP-2 signaling. Mechanistically, Dyn2 regulates PDGFRa-stimulated glioma cell growth and invasion through interaction with activated PDGFRa, SHP-2 and PI3K as well as Src-dependent protein phosphorylation.
Results
Depletion of Dyn2 inhibits PDGFRa-stimulated glioma cell migration in vitro To determine the role of Dyn2 in PDGFRa-regulated glioma cell growth and invasion, we first examined the expression of Dyn isoforms in various glioma cell lines, mouse fibroblasts (NIH3T3) and astrocytes (mAst). As shown in Figure 1a , Dyn1 is expressed at low levels in all cell lines examined. Dyn3 is highly expressed in LN428, U138, LN443, T98G, LN235 and NIH3T3 cells but at low levels in other cell lines. In contrast, Dyn2 was found at high levels in all cell lines analyzed. To determine the function of Dyn2, we chose SNB19 and LN444 cells with high levels of Dyn2. We first knocked down Dyn2 using lentivirus-encoded short hairpin RNAs (shRNAs) in LN444 and SNB19 glioma cells that were stimulated with PDGF-A (PDGF-A only activates PDGFRa; Tallquist and Kazlauskas, 2004) . As shown in Figure 1b and Supplementary Figure S1 , knockdown of Dyn2 in these glioma cells by two separate shRNAs but not a control shRNA reduced PDGF-A-induced phosphorylation of Akt and extracellular signal-regulated kinases 1 and 2 (Erk1/2) as well as GTP loading of Rac1 and Cdc42, two critical small GTPases that mediate Dyn-modulated cell motility (Kruchten and McNiven, 2006) Figure S2) . Interestingly, depletion of Dyn2 by shRNAs did not affect glioma cell migration stimulated by fetal bovine serum (FBS), epidermal growth factor and hepatocyte growth factor (Supplementary Figure S3) , suggesting that Dyn2 is important and specific for PDGFRa-promoted glioma cell migration.
Knockdown of Dyn2 suppresses PDGFRa-stimulated glioma tumor growth and invasion in vivo To determine the function of Dyn2 in PDGFRapromoted glioma tumorigenesis, we knocked down Dyn2 in LN444/PDGF-A cells that expressed exogenous PDGF-A (Liu et al., 2011) by two different lentivirus-encoded shRNAs (1 and 2) and a control shRNA. As shown in Figure 2A , B70% of endogenous Dyn2 in puromycin-resistant cell populations was reduced in LN444/PDGF-A/shRNA cells when compared with the control shRNA cells. In vitro, depletion of Dyn2 in LN444/PDGF-A cells had a minimal impact on cell proliferation when compared with that of LN444/GFP or control shRNA cells ( Figure 2B ). However, knockdown of Dyn2 markedly attenuated PDGF-A/PDGFRa-stimulated cell survival ( Figure 2C ) and migration (data not shown). Additionally, treatment of LN444/PDGF-A/shDyn2 cells with AG1296, an inhibitor for PDGFR, has no effect on PDGF-Astimulated cell proliferation ( Figure 2B ) and survival ( Figure 2C ) and migration (not shown), suggesting that Dyn2 is not at upstream of PDGFR in glioma cells. These data suggest that under these experimental conditions, inhibition of Dyn2 by shRNA knockdown only affects PDGF-A-promoted glioma cell survival but not cell growth in vitro.
Next, we examined the function of Dyn2 in PDGFRa-promoted glioma tumorigenesis in vivo. In the brains of mice, LN444/PDGF-A glioma cells formed highly tumorigenic and invasive gliomas, whereas LN444/GFP cells only established small and noninvasive tumors (Liu et al., 2011) . Thus, we separately implanted LN444/PDGF-A/control-shRNA (shControl) and LN444/PDGF-A/Dyn2-shRNA (shRNA 1 and shRNA 2) cells into the brains of mice. As shown in Figure 2D , compared with control LN444/PDGF-A Figure 2G ). Similarly, when compared with LN444/PDGF-A/control shRNA tumors, LN444/ PDGF-A/shRNA 1 and shRNA 2 tumors displayed a marked increase in cell apoptosis ( Figure 2D , compare j with k and l, Figure 2H ). Taken together, these results suggest that Dyn2 is important for PDGFRa-promoted glioma cell growth and invasion in vitro and in vivo.
Dyn2 mediates PDGFRa-stimulated glioma cell migration through PI3K and SHP-2 Dyn was previously shown to interact with PI3K in PC12 cells stimulated by PDGF (Scaife et al., 1994) . As PI3K and SHP-2 mediate PDGFRa-stimulated glioma tumor growth and invasion in the brains of mice (Liu et al., 2011) and Dyn interacts with PI3K (Scaife et al., 1994) , we hypothesized that Dyn2 mediates PDGFRa-SHP-2-stimulated glioma cell migration. To test this hypothesis, we first transiently transfected wild-type (WT) HA-Dyn2, DN HA-Dyn2-K44A mutant or a vector control into SNB19 and LN444 glioma cells, respectively. After validating the expression of exogenous Dyn2 by immunoblotting (Supplementary Figure  S4A) , we determined the impact on glioma cell migration by in vitro cell migration assays. As shown in Supplementary Figure S4B , compared with the control SNB19 or LN444 cells, overexpression of WT Dyn2 did not significantly affect PDGFRa-stimulated glioma cell migration. However, expression of a DN Dyn2-K44A mutant significantly attenuated PDGF-Astimulated cell migration of both cell lines. Thus, these data suggest that Dyn2 is important for PDGFRastimulated glioma cell migration. Next, we determined whether Dyn2 interacts with SHP-2 and PI3K in SNB19 and LN444 cells stimulated by PDGF-A. As expected, PI3K was associated with Dyn2 in PDGF-A-treated glioma cells. Interestingly, Dyn2 also binds to SHP-2 in PDGF-A-stimulated glioma cells ( Figure 3A) , suggesting an involvement of Dyn2 in PDGFRa-SHP-2-stimulated glioma cell migration. To examine this possibility, we treated SNB19/WT HA-Dyn2 and SNB19/Control cells with inhibitors of PI3K (LY294002) or SHP-2 (PHPS-1 or NSC87877) with or without PDGF-A stimulation. As shown in Figure 3B , inhibition of PI3K or SHP-2 by their inhibitors effectively abrogated PDGF-A-stimulated glioma cell migration whereas overexpression of a WT HA-Dyn2 by SNB19 glioma cells did not fully but partially rescued the inhibitory effects by these inhibitors on PDGF-A-stimulated cell migration, suggesting Dyn2 as an effector downstream of the PDGFRa-PI3K/ SHP-2 signaling. To further study this signaling, we examined the subcellular distribution of PDGF-Astimulated Dyn2, cortactin (a Dyn2-binding protein that involves in PDGF-stimulated actin remodeling) (Krueger et al., 2003) and PDGFRa in serum-starved SNB19 cells that were transiently transfected with a WT Dyn2-GFP and pretreated with or without LY294002, followed by PDGF-A stimulation. As shown in Figure 3C , consistent with previous reports ( Overexpression of HA-Dyn2 partially rescued the inhibitory effect of PI3K and SHP-2 inhibitors on PDGFRa-promoted glioma cell migration. Cells generated from (A) were serum starved for 24 h, and then pretreated with or without LY294002 (10 mM), PHPS-1 (100 mM) and NSC87877 (100 mM) for 1 h on ice and analyzed by in vitro cell migration assays for 8 to 10 h as described in Figure 1c Figure S5 . Serum-starved SNB19 cells transiently transfected with a WT Dyn2-GFP were pretreated with 10 mM LY294002 for 1 h followed by 5-min stimulation with 50 ng/ml PDGF-A. Cells were then separately stained with anti-cortactin or anti-PDGFRa antibodies followed by secondary antibodies conjugated with different fluorophores (scale bar, 15 mm). N, nuclear; red arrows indicate colocalization of Dyn2 and cortactin or Dyn2 and PDGFRa at the invasion fronts; white arrows indicate Dyn2-GFP localized to the pericantriolar material and centrioles. Results in (A-C) represent two to three independent experiments with similar results.
inhibitor LY294002 blocked their redistribution and colocalization at the invasion fronts of cells ( Figure 3Cc and f and Supplementary Figure S5g -i and p-r). Taken together, these data show that activation of PDGFRa induces the association of Dyn2 with PI3K and SHP-2, and colocalization of PDGFRa, Dyn2 and cortactin, thereby augmenting PDGFRa-stimulated glioma cell migration.
SHP-2 mediates interaction of Dyn2 with activated PDGFRa Next, we assessed whether inhibition of SHP-2 affects the association between Dyn2 and PDGF-A-activated PDGFRa by knockdown of endogenous SHP-2 with a SHP-2 siRNA. As shown in Figure 4a , siRNA depletion of SHP-2 significantly decreased association of Dyn2 with activated PDGFRa compared with the control in PDGF-A-stimulated SNB19 and LN444 cells. Furthermore, impairment of association of Dyn2 with PDGFRa by knockdown of SHP-2 also markedly inhibited PDGF-A-stimulated Rac1 and Cdc42 activities ( Figure 4a , lower panels) and glioma cell migration ( Figure 4b ). Thus, these data suggest that SHP-2 mediates Dyn2 binding to activate PDGFRa, thereby promoting Rac1 and Cdc42 activities and glioma cell migration.
PRD domain of Dyn2 is necessary for its association with SHP-2
It has been demonstrated that Dyn2 interacts with various Src homology (SH)-domain-containing endocytic adaptor proteins through its proline-rich domain (PRD) (Gout et al., 1993; Kruchten and McNiven, 2006) . To determine whether the PRD domain of Dyn2 is required for its association with SHP-2, we transiently transfected SNB19 cells with WT HA-Dyn2, a Dyn2 mutant lacking its PRD domain (HA-DPRD) or a vector control. As shown in Figure 5a , PDGF-A stimulation of SNB19 cells induced the association of WT Dyn2 with SHP-2 and GTP-loading activities of Rac1 and Cdc42, whereas the Dyn2 DPRD mutant failed to bind to SHP-2 and also inhibited PDGF-Astimulated Rac1 and Cdc42 activities in SNB19 cells ( Figure 5a ). Next, we assessed the impact of loss of the association between Dyn2 and SHP-2 on PDGFRastimulated cell migration. As shown in Figure 5b , expression of WT Dyn2 did not significantly affect PDGF-A-induced cell migration, whereas introduction of the DPRD mutant markedly impaired the PDGF-Astimulated cell migration. Taken together, these data indicate that Dyn2 induces PDGFRa-SHP-2-promoted glioma cell migration through interaction with SHP-2 via its PRD domain.
PDGFRa-SHP-2 induces glioma cell migration through Src-dependent tyrosine phosphorylation of Dyn2 SHP-2 is a ubiquitously expressed non-transmembrane PTP and essential in RTK signaling pathways (Chan et al., 2008; Matozaki et al., 2009) . Thus far, we demonstrated that the interaction of SHP-2 and Dyn2 is required for PDGFRa-stimulated glioma cell migration. To assess whether the activity of SHP-2 is required for Dyn2 function, we expressed a Myc-Histagged DN C459S SHP-2 (catalytically inactive) mutant in SNB19 cells. As expected, the C459S SHP-2 mutant decreased PDGFRa-induced p-Akt (Figure 6a ) and PDGFRa-promoted cell migration (Figure 6b ). However, SHP-2 C459S mutant retained its ability to associate with PDGFRa induced by PDGF-A ( Figure 6a ). Next, as p-Y of Dyn2 is critical for its function Weller et al., 2010) , we examined the impact of loss of SHP-2 activity on the induced p-Y of Dyn2. As shown in Figure 6c , expression of a DN C459S SHP-2 mutant, but not a WT SHP-2, markedly inhibited PDGF-A-induced p-Y of Dyn2. Furthermore, expression of C459S SHP-2, but not , it is possible that PDGF-A-activated Src induces p-Y of Dyn2, leading to increased cell migration. To test this hypothesis, we treated PDGF-A-stimulated SNB19 cells with two separate Src family kinase (SFK) inhibitors, PP2 and SU6656, and found that the inhibition of SFK activity significantly reduced PDGF-A stimulation of p-Y of Dyn2 (Figure 6e ) and cell migration in vitro (Figure 6f) .
Last, we investigated the roles of SHP-2 in recruiting Dyn2 to activated PDGFRa and Src in induction of p-Y of Dyn2 using mouse Ink4a/Arf-null astrocytes that separately express PDGFRa WT and its various mutants (Liu et al., 2011) . As shown in Figure 6g and Supplementary Figure S6 , p-Y of Dyn2 and Dyn2 association with activated PDGFRa in these mouse astrocytes were because of PDGF-A stimulation of endogenous PDGFRa in the astrocytes as these cells are not PDGFRa deficient (Liu et al., 2011) . Taken together, these data suggest that SHP-2 activity is required for PDGFRa stimulation of p-Akt, p-Y of Dyn2, the association between Dyn2 and PDGFRa and glioma cell migration, and that Src-dependent p-Y of Dyn2 mediates PDGFRa-induced glioma cell migration.
Discussion
In this report, as illustrated in a working model (Figure 7 ), we demonstrated a mechanism by which Dyn2 regulates PDGFRa-SHP-2/PI3K-stimulated glioma tumor growth and invasion. By using an established in vivo glioma model that activation of the PDGFRa-SHP-2/PI3K signaling promotes glioma growth and invasion in the brain (Liu et al., 2011) , we identified Dyn2 as a downstream effector for PDGFRa-induced glioma cell migration and survival in vitro, and tumor growth and invasion in vivo. Dyn2 mediates PDGFRa stimulation of glioma cell migration through association with SHP-2 and PI3K via its PRD domain, association and colocalization with the activated PDGFRa and activation of Rac1 and Cdc42. Inhibition of SHP-2 by siRNA knockdown, a DN SHP-2 mutant, SHP-2 inhibitors, deletion of the PRD domain of Dyn2 or a mutation of the SHP-2-binding site of PDGFRa suppressed PDGFRa-Dyn2-stimulated phosphorylation of Akt and Erk1/2, Rac1 and Cdc42 activities, and glioma cell growth and migration, thereby establishing a link of SHP-2 and Dyn2 with PDGFRa activation. Furthermore, we show that SHP-2 activity is required for Src-dependent p-Y of Dyn2, which is critical for PDGFRa-stimulated glioma cell migration.
One of the important aspects of this work is the identification of Dyn2 as a downstream modulator for PDGFRa-SHP-2-stimulated glioma tumor growth and invasion. Dyn has been implicated in PDGFstimulated cell migration through changing its own cytoplasmic distribution in fibroblasts (McNiven et al., 2000b) . Disruption of Dyn2 function altered Rac localization and inhibited Rac-dependent cell spreading and lamellipodia formation in PDGF-induced macropinocytosis in fibroblasts even though Rac was activated (Schlunck et al., 2004) . Interestingly, Dyn is also recently implicated in the promotion of cancer cell proliferation (Joshi et al., 2010) . Small-molecule inhibitors of Dyn (myristyl trimethyl ammonium bromides (MiTMABs)) competitively impaired the ability of Dyn to bind phospholipids and abrogated receptormediated endocytosis. Cells treated with Dyn inhibitors (MiTMAB and octadecyltrimethyl ammonium bromide) prevented the growth of a wide range of human cancer cells but had much less effects on nontumorigenic fibroblast cells (Joshi et al., 2010) . Our results are consistent with these studies. We show that Dyn2 is essential for PDGFRa-SHP-2-stimulated Akt, Erk1/2, Rac1 and Cdc42 activities, and glioma tumor growth and invasion. Depletion of Dyn2 by shRNAs inhibited these PDGFRa-stimulated signaling, glioma cell migration and survival in vitro, and tumor growth and invasion in the brains of mice. Overexpression of WT Dyn2 did not significantly affect PDGF-A-induced cell migration, whereas a DN Dyn2-K44A mutant or a Dyn2 DPRD mutant incapable of associating with SHP-2 impaired the PDGFRa stimulation. Taken together, these results establish a link between Dyn2 and activation of the PDGFRa-SHP-2 signaling, leading to an enhanced glioma tumor growth and invasion.
The second important finding in this study is that our data reveal a collaborative function of Dyn2 and SHP-2 to mediate PDGFRa-stimulated glioma cell invasion. A previous study showed that poliovirus (PV) infection of cultured human brain microvascular endothelial cells depends on Dyn-dependent caveolar endocytosis, and intracellular virus triggered the PV receptor (PVR) signals through the association of PVR with SHP-2 (Coyne et al., 2007) . In breast cancer, prolactin and insulin-like growth factor I (IGF-I) regulate the pathogenesis and progression together through increasing proliferation, survival and invasion. SFK activity is required for IGF-IR association with SHP-2, and knockdown of Dyn2 reduces SHP-2 association with IGF-IR (Carver et al., 2010) . Our results in this study suggest that Dyn2 mediates PDGFRa-SHP-2-stimulated glioma cell growth and invasion through interaction with SHP-2 upon PDGFRa stimulation. Moreover, inhibition of SHP-2 by siRNA depletion, SHP-2 inhibitors, disruption of SHP-2 binding to Dyn2 or mutation of SHP-2-binding site of PDGFRa (F720) abrogated Dyn2 binding to activated PDGFRa, and PDGF-A-stimulated cellular signaling and glioma cell migration, demonstrating that Dyn2 mediates the PDGFRa-SHP-2 signaling in promoting glioma cell growth and invasion in vitro and in vivo.
The last novel finding in this study is that SHP-2-mediated Dyn2 phosphorylation via Src is essential for PDGFRa-stimulated glioma cell migration. Src plays an important role in regulating the endocytosis of PDGFRb-G-protein-coupled receptor complexes, in which Src induces p-Y of Gab1 (Grb-2 associated binder 1) and promotes accumulation of Dyn2 at the plasma membrane (Waters et al., 2005) . Src is recently found to activate Dyn2 by phosphorylation to induce Golgi fragmentation (Weller et al., 2010) . Moreover, Src-dependent p-Y of Dyn2 and its associated actinbinding protein, cortactin, regulate clathrin-mediated endocytosis of transferrin in epithelial cells . Additionally, SHP-2 activates Src kinase by inhibiting the recruitment of C-terminal Src kinase, which exerts its inhibitory role by phosphorylating Src Y529 (Zhang et al., 2004) . Furthermore, during angiogenesis, vascular endothelial growth factor A (VEGF-A)-mediated VEGF receptor 2 (VEGFR-2) activation is downregulated by collagen I but not vitronectin. SHP-2 is recruited to the activated VEGFR-2, and then promotes p-Y of Dyn2 via Src to mediate VEGFR-2 internalization (Mitola et al., 2006) . Consistent with these reports, our data not only validate that Src-dependent p-Y of Dyn2 induced by PDGFRa activation is critical for glioma cell migration, but also demonstrate that SHP-2 activity is required for Srcdependent p-Y of Dyn2, underscoring the link between Dyn2 and SHP-2 with PDGFRa-Src activation in promoting glioma cell migration. However, although we show that Src induces p-Y of Dyn2 and Src inhibitors exert an opposite effect, we cannot rule out the involvement of other members of the SFK family or other non-RTKs in this process. This possibility is illustrated by a study that cortactin, a partner of Dyn, can stimulate cell motility (Kowalski et al., 2005) , and is phosphorylated by SFKs as well as Abl and Arg (Wu et al., 1991; Boyle et al., 2007) . In addition, Dyn2 also binds to Grb2, Dock4 (a Rac1 guanine exchange factor) and PDGFRb, forming a ternary complex to regulate PDGF-dependent cell migration on fibroblasts (Kawada et al., 2009) . These alternative possibilities of how Dyn2 is involved in the PDGFRa-SHP-2 signaling in promoting glioma cell invasion warrant further investigation.
In summary, this study provides novel insights into the mechanisms by which Dyn2 mediates the PDGFRa-SHP-2/PI3K signaling through a SHP-2-induced and Src-dependent p-Y of Dyn2 in glioma cells. Our data identified Dyn2 as an effector downstream of the PDGFRa-SHP-2 signaling, critical in promoting glioma cell migration in vitro and tumor growth and invasion in vivo. As Dyn2 is essential for various cell biological functions including cell motility and proliferation, our study suggests that targeting the PDGFRa-SHP-2-Dyn2 signaling may be beneficial for treatments of patients with glioblastomas and other types of human cancers that overexpress PDGFRa.
Materials and methods
In vitro cell migration assays In vitro cell migration assays were performed as we previously described (Imanishi et al., 2007) . Briefly, 5 Â 10 5 cells/ml in 50 ml of Dulbecco's modied Eagle's medium plus 0.5% FBS were separately placed into the top wells of a Boyden chamber. The bottom wells contained 50 ng/ml PDGF-A or epidermal growth factor, 40 ng/ml hepatocyte growth factor, 10% FBS or vehicle with or without indicated inhibitors. The cells were allowed to migrate through an 8-mm pore size membrane precoated with fibronectin (10 mg/ml) for 8-10 h at 37 1C. Afterwards, the membrane was fixed and stained, nonmigrating cells were removed and the remaining cells were counted. Six high-power fields (total magnification, Â 200) from each sample were randomly selected. Data were normalized to the stimulated control (100%) and analyzed using the GraphPad Software (GraphPad Software Inc., San Diego, CA, USA).
Living cell fluorescence real-time imaging SNB19 cells expressing a nuclear-located H2A-GFP protein were seeded onto 35 mm No. 1.5 coverslip bottom dishes. After 24 h of serum starvation, the medium was replaced with fresh medium with or without 50 ng/ml PDGF-A plus 0.5% FBS and incubated at 37 1C, 5% CO 2 coupled to a spinning disk UltraVIEW RS confocal imaging system (Perkin Elmer, Boston, MA, USA). Cells were imaged at 10 min intervals, using a 300 ms exposure time during the 12 h time course. Images were compiled into a QuicktimeTM movie using the software Velocity (Improvision, Coventry, UK).
Cell proliferation and apoptosis MTT (3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide) assay. Various cells were seeded onto 96-well plates at a density of 4000 per well, 6 replicates per cell line. After overnight incubation, the medium was replaced with fresh Dulbecco's modied Eagle's medium plus 0.5% FBS containing 2 mM AG1296 or vehicle. At indicated times, 50 ml MTT (2 mg/ ml in phosphate-buffered saline) was added to each well and incubated at 37 1C for 4 h. MTT reduction by viable cells was measured colorimetrically at 570 nm using a Microplate Reader.
TUNEL assay. Various cells were plated on eight-well chamber slides. After overnight incubation, the medium was replaced with fresh Dulbecco's modied Eagle's medium plus 0.5% FBS with 2 mM AG1296 or vehicle. After 48 h, slides were fixed by 4% formaldehyde in ice-cold phosphate-buffered saline and permeabilized with 0.2% Triton X-100 solution. After equilibration, slides were immersed in TUNEL (TdT-mediated dUTP nick end labeling) reaction buffer at 37 1C for 60 min inside the humidified chamber. Reaction was stopped by 2 Â saline sodium citrate and slides were counterstained with Hoechst 33 258 and mounted. A total of 1000 cells of each slide were randomly examined and numbers of TUNEL-positive cells were counted under a microscope equipped with a SPOT digital camera.
Immunofluorescent staining and confocal microscopic analyses SNB19 cells transiently transfected with Dyn2-GFP were plated on glass coverslips in media with 10% FBS. After overnight incubation, the medium was replaced with fresh Dulbecco's modied Eagle's medium containing 0.5% FBS. The cells were cultured for an additional 24 h, pretreated with 10 mM PI3K inhibitor, LY294002, for 1 h, and then stimulated with 50 ng/ml PDGF-A for 5 min. After the treatment, coverslips were washed and fixed by 4% formaldehyde in ice-cold phosphate-buffered saline and permeabilized with 0.2% Triton X-100 solution. After equilibration, slides were stained with anti-cortactin (1:300) and anti-PDGFRa (1:50) antibodies in AquaBlock reagent (East Coast Bio, North Berwick, ME, USA) in phosphate-buffered saline at 4 1C overnight, and then re-stained with secondary antibodies. Coverslips were mounted and examined under an Olympus Fluoview 1000 Confocal (Olympus Imaging America Inc., Center Valley, PA, USA) equipped with a digital camera.
Statistical analyses
One-way analysis of variance or an unpaired, two-tailed Student's t-test followed by Newman-Keuls post-test was performed using the GraphPad Prism software. A P-value of p0.05 was considered statistically significant.
Cell culture, DNA constructs, antibodies and reagents, immunoprecipitation and immunoblotting, RNA interference, brain tumor xenograft and immunohistochemical analyses are described in the Supplementary Information.
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